GPC3/​Mesothelin-CAR-γδT Cells Against Cancers

January 12, 2024

Primary Outcome Measures

  • Number of Patients with Dose Limiting Toxicity

Secondary Outcome Measures

  • Percent of Patients with best response as either complete remission or partial remission.
  • Median γδT cell persistence

Inclusion Criteria

1. Patients with advanced cancer that expresses GPC3 or Mesothelin protein; 2. Life expectancy >12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available autologous transduced T cells with greater than or equal to 20% expression of GPC3/Mesothelin-CAR determined by flow-cytometry and killing of Mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

Exclusion Criteria

  1. Had accepted gene therapy before;
  2. Severe virus infection such as HBV, HCV, HIV, et al;
  3. Known HIV positivity;
  4. Active infectious disease related to bacteria, virus,fungi,et al;
  5. Other severe diseases that the investigators consider not appropriate;
  6. Pregnant or lactating women;
  7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
  8. Other conditions that the investigators consider not appropriate. –
CONTACT INFORMATION

Name*
Address*
Have you received a diagnosis?*
DIAGNOSIS
MM slash DD slash YYYY
This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact